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Commentary
The Role of Gene and Cell Therapy in the Era
of Health Care Reform
Walter H. Ettinger, MD, MBA, and Terence R. Flotte, MD
After nearly thirty years of biological discoveryunderpinning gene therapy vectors and more than
twenty years of clinical gene therapy trials, cases with clear
evidence of clinical efficacy have now been demonstrated.
Examples include restoration of immune function in children
with X-linked severe combined immune deficiency (X-SCID)
and chronic granulomatous disease (CGD), restoration of
vision in Leber Congenital Amaurosis (LCA), and marked
improvement in motor function of Parkinson disease (PD).
Likewise, cell-based therapies beyond the well-established
bone marrow transplant techniques are emerging, including
the use of mesenchymal (MSC) and hematopoietic (HSC)
bone marrow stem cells, umbilical cord cells, human embry-
onic stem (hES) cells and induced pluripotent stem (IPS) cells.
Applications for these new forms of cell-based therapies in-
clude a variety of neurodegenerative disorders (such as
amyotrophic lateral sclerosis [ALS]) and ophthalmologic
disorders, such as age-related macular degeneration.
At the same time U.S. spending for health care has been on
an unyielding upward path—reaching $2.5 trillion in the
aggregate, $8,100 per person, and 17.6 percent of gross do-
mestic product (GDP) in 2009 (Schoenman and Chockley,
2011). The ever-rising cost of health care has serious conse-
quences for individuals and the country. For example, from
1999–2009 health care costs cancelled out real income gains
for an average U.S. family (Auerbach and Kellerman, 2011),
and the 2011 Medicare Trustees report projects that Medi-
care has an unfunded liability of over $38 trillion (www
.cms.gov/ReportsTrustFunds/downloads/tr2011.pdf ). The
unfunded liability is the difference between the benefits that
have been promised to current and future retirees and what
will be collected in dedicated taxes and Medicare premiums.
These facts have led to proposals that radically redesign the
funding of health care in the United States, with the goals of
providing access to care for all Americans, improving
quality, and reducing costs. Ironically, the emergence of all
the potential promise of these innovative molecular thera-
pies is coinciding with a future in which the costs of new
therapies may be the major determinate of whether they will
be available to patients.
Is there a future state that will embrace the equally noble
goals of using cutting-edge science to devise advanced bio-
logical therapeutics for previously untreatable illnesses and
of using systems engineering to provide all Americans with
the lowest cost care possible? The answer is far from certain.
What is clear is that if cost-effectiveness is to be addressed in
the context of gene and cell therapy, it will have to include a
long time-horizon in which the therapy may avoid or ame-
liorate complications of the disease and accurate monetiza-
tion of the gains in quality of life and function for the
individuals who are treated. Incorporating these elements
into an economic model of the value of gene and cell therapy
is challenging but not unprecedented. What is even more
problematic is the uncertainty about what the new payment
models will include, and whether such models are truly
suited to look at global lifelong benefits to patients.
Possible New Payment Models in the Reform Era
On-average health care spending per person has grown
over two percentage points faster than per capita GDP for the
last 40 years. The reasons for the continuous increase in costs
are aging of the population, personal income growth, supply
induced demand, defensive medicine, and administrative
costs (Congressional Budget Office, 2008). In addition, a third
party fee-for-service payment system that encourages the use
of new technology in medical practice (Congressional Budget
Office, 2008; Roehrig and Rousseau, 2011). The spread of new
and often expensive diagnostic and therapeutic modalities is
the leading factor, accounting for fifty percent of the growth in
real per capita health care spending care providers and sup-
pliers to raise prices and increase the volume and complexity
of services, has fueled the rise in costs. bAU2
On March 23, 2010, President Barack Obama signed into
law the Patient Protection and Affordable Care Act (PPA-
CA), whose overriding goals were to make health insurance
accessible to all Americans and to decrease the rate of rise in
health care costs. Moreover, private insurance companies are
beginning to explore new payment methodologies that focus
on the Total Cost of Care (TCOC). The TCOC experiments
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aim to change the payment mechanisms for care from purely
fee-for-service payments based on volume to a fee-for-value
payment system that links payments to the rate of growth in
total cost of care provided to a patient annually (Morris and
Eggbeer, 2011). The ‘‘fee-for-value’’ may be accomplished
through a number of payment mechanisms, examples of
which are provided inT1c Table 1. Each of these mechanisms has
the advantage for the insurer of sharing with the providers
some aspect of the ‘‘risk’’ of care being more expensive than
predicted.
One may note that in each of these cases the term ‘‘pro-
vider’’ is not precisely defined. This is because the total cost
of care for an individual (under capitation or shared sav-
ings), or for an episode of illness (under a bundled payment),
may actually be split between primary care physicians,
specialist physicians, hospitals, clinics, providers of ancillary
diagnostic services (radiology and laboratory), and providers
of rehabilitation services (either in rehabilitation facilities or
in the home). In previous systems, each of these individual
providers would bill and collect from the insurer for any
covered services they provided. Because of the insurers’ in-
terest in containing the entire cost of providing care to an
individual or population, there has been a movement to
aggregate these costs together and hold a single entity
accountable for the total cost of care. These so-called ‘‘Ac-
countable Care Organizations’’ (ACOs) do not yet exist, but
could take the form of fully integrated corporate structures
employing all of the providers and resources mentioned
above, or could take the form of consortia of organizations
agreement to jointly enter contractual arrangements with the
provider.
The Center for Medicare and Medicaid Services (CMS) has
recently published draft guidelines (for public comment) on
how Medicare might recognize an ACO as being eligible to
enter into a gain-sharing style arrangement for the coverage
of Medicare beneficiaries. These proposed guidelines view
savings in health care cost over a year-to-year basis. Thus, a
high-cost, high-impact therapy, such as a stem cell transplant
or a gene therapy administration, might not fare so well
initially under such a plan, particularly if the cost of the
therapy was accrued in a single year.
Cost Justification for High-Cost,
High-Impact Interventions
There are three fundamental arguments in favor of high-
cost, high-impact interventions, such as a hypothetical sight-
restoring gene therapy for LCA or a life-sustaining stem cell
therapy for ALS. First, these therapies could decrease the
utilization of other resources in later years, particularly if
patients become healthier and utilize emergency room visits,
hospital stays, long term care, and other therapies less fre-
quently. This would be a fairly conventional rationale for any
‘‘primary prevention,’’ although the time-horizon for the
payback of the high-cost, high-impact therapy could stretch
over a number of years.
Second, high-cost, high-impact therapies could improve
the patient’s quality of life in a manner that might result in
generating a greater economic impact on the society, as-
suming they might be able to return to work, pay taxes, and
utilize less disability services. These costs could also be
quantified utilizing fairly standard techniques in economics.
Finally, the value of a life saved or of vision restored has
long been recognized and acknowledged by our society,
even above and beyond the decrease in utilization of other
health care resources and the restoration of the individuals
economic productivity. Nevertheless, new therapies will re-
ceive much more scrutiny than in the past, and a strong case
will need to be made to justify their costs by provider
organizations (Fuchs, 2011).
Gene and Cell Therapies as Platform Technologies
One additional aspect of gene and cell therapeutics is the
promise of a ‘‘second wave’’ of therapeutics. While this first
wave of agents proving to be clinically efficacious are tar-
geted to rare (often single gene disorders), there is hope that
these successes will lay the groundwork (i.e., become a
technology platform), for future gene and cell-based thera-
pies for disorders with much higher incidence rates, such as
diabetes, coronary artery disease, stroke, and Alzheimer’s
disease. In these latter cases, the total societal costs of the
diseases are better characterized, and even partial reductions
of these costs could be more readily assessed. Nonetheless,
taking care to measure the cost benefit of such therapies will
be important in assuring acceptance by payers, providers,
and patients. The quicker gene and cell therapy move from
the first phase to the second, the more readily demonstrable
the societal benefits may be.
Summary
The full realization of the impact of gene and cell therapies
on human diseases will take place in a health-care payment
environment that is not particularly well designed to weigh
the advantages and disadvantages of such interventions. In
fact, noted scholars are calling for a retrenchment from high
technology therapies and using scarce societal resources on
primary care and public health (Callahan and Nuland, 2011).
However, history would suggest that other high-cost, high-
impact interventions, such as bone marrow and solid organ
transplantation, open heart surgery, and advanced radiation
Table 1. Examples of New Risk-based Payment Mechanisms
Payment Model Brief Description




Insurer pays fixed amount for a single episode of illness, to be divided among providers
by mutual agreement.
Shared Savings Insurer predicts annual cost of health care (based on severity of illness and historic medical inflation)
and shares any savings from this predicted cost with the providers.
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therapies (such as proton beam therapy), can and will be
introduced if they provide better outcomes for patients in the
long run. If our scientific community is able to demonstrate
these long-term benefits in quality or quantity of life, these
advanced therapies seem likely to move forward to general
use despite their unconventional cost structures.
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